online

Riaz Dawood - About resistant hypertension in South Africa

Riaz Dawood (South Africa) answers the following questions:

- Please tell us about the prevalence of hypertension and especially resistant hypertension in South Africa
- Who refers the resistant hypertensive patients to you?
- What experience do you have with device-based treatments in South Africa?
- What did you enjoy at the RHC 2014 in Berlin?
- How did the update on the Symplicity HTN-3 trial affect your work?

 

Roland Schmieder - On the Symplicity HTN-3 press release and hypertension treatments

Roland Schmieder (Germany) answers the following questions:

- Please share with us your thoughts on the Symplicity HTN-3 press release
- How has this new information impacted your clinical practice as related to renal denervation?
- What is the vision of ESH on this matter?
- What are the most significant advancements in hypertension treatments in the past 5 years?

 

To leave a comment, please create your free account here !

Markus Schlaich discussing the "fil rouge" patients presented during RHC 2014

Markus Schlaich (Australia) answers the following questions:

- Can you tell us more about the RHC "fil rouge" patients presented in Berlin, and the objectives of using these patients?

- Please tell us more about your preferred therapy for the elderly patient, the metabolic patient and the young adrenergic patient

- What was your favorite session at RHC 2014 and why?

 

To leave a comment, please create your free account here !

Michel Burnier on Drug Adherence and Compliance

Michel Burnier (Switzerland) answers the following questions:

- Please explain the difference between drug adherence and drug compliance.

- What is the role of adherence in resistant or difficult to control hypertension? (30-40% of patients are not adherent)

- How do you control drug compliance in daily clinical practice in your patients?

- Where do you see the role of the GP in the adherence system of a patient?

Pages